Global Commercial Strategy (GCS) Oncology: Senior Director, Portfolio Strategy

Role Summary: The Senior Director, Oncology Portfolio Strategy is a senior strategic leader responsible for shaping the long-term Oncology portfolio strategy and investment agenda. The Oncology portfolio represents a significant opportunity to advance Pfizer's ambition to deliver breakthrough therapies for patients with cancer and related serious conditions. This role will contribute to that ambition by leading the development of commercial portfolio strategies across tumor types, modalities, and innovation platforms, enabling disciplined investment decisions that maximize patient impact and portfolio value. The position serves as a key thought partner to Oncology leadership, translating scientific, clinical, commercial, competitive, and financial insights into enterprise-level recommendations. Working across Research, Development, Commercial, Medical, Access, Business Development, and Finance, the Senior Director drives portfolio prioritization, resource allocation, external innovation assessments, and long-range strategic planning to ensure Pfizer's Oncology portfolio remains differentiated and competitive. This role will also help evolve portfolio management frameworks, governance processes, and decision-support capabilities to strengthen strategic decision-making across the Oncology organization. The Senior Director will partner closely with R&D, Medical Affairs, Global Access Strategy & Pricing (GASP), Global Commercial Analytics (GCA), Competitive Intelligence, Regulatory, Business Development, US, Global and International Commercial / Marketing leadership. The Senior Director will help advance disciplined trade-off decisions, long-range portfolio thinking, and AI-enabled ways of working that support patient impact and enterprise value realization for the Oncology portfolio. Responsibilities: Portfolio Strategy & Long-Range Planning: • Lead development and evolution of the Oncology portfolio strategy, identifying the highest-value opportunities across tumor types, mechanisms, modalities, and therapeutic platforms. • Develop long-range portfolio scenarios and strategic roadmaps that inform future investment priorities and portfolio evolution. • Assess portfolio strengths, gaps, risks, and opportunities to support proactive decision-making and resource allocation. • Drive portfolio-level strategic trade-off discussions, balancing scientific opportunity, probability of success, patient impact, and commercial value. • Translate complex scientific and market dynamics into actionable portfolio recommendations for senior leadership. Investment Strategy & Governance: • Serve as a strategic advisor to Oncology leadership on portfolio prioritization and capital allocation decisions. • Lead development of portfolio recommendations for governance committees and enterprise decision-making forums. • Establish and maintain frameworks that improve consistency, rigor, and transparency in portfolio evaluations. • Drive enterprise discussions on investment prioritization, development sequencing, indication expansion, and lifecycle optimization. • Support to Enterprise / PMT request for assessments / valuations. • Support critical portfolio reviews and recommendation development for senior executive stakeholders. Enterprise Insight Generation: • Integrate scientific, clinical, epidemiologic, access, policy, patient, competitive, and commercial insights into cohesive portfolio strategies. • Monitor emerging oncology trends and evolving standards of care to identify potential portfolio implications. • Evaluate disruptive technologies, novel modalities, and future treatment paradigms that may alter portfolio priorities. • Develop strategic perspectives on the future evolution of the oncology landscape and the resulting implic